{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-275985","form_type":"8-K","ticker":null,"cik":"0001305253","company_name":"Eiger BioPharmaceuticals, Inc.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.570633+00:00","generated_at":"2026-06-08T04:41:30.566231+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Eiger BioPharma receives Nasdaq equity deficiency notice; delisting risk elevated","bullets":["Received Nasdaq deficiency letter on Nov 10, 2023 for failing $10M stockholders' equity requirement.","Must submit compliance plan by Dec 26, 2023; if accepted, extension to May 8, 2024.","Also has bid price deficiency (below $1.00) with compliance deadline Jan 22, 2024; likely ineligible for extra extension due to equity shortfall.","Stock continues trading under EIGR on Nasdaq pending potential delisting appeals."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-275985","json":"https://secwatch.observer/filing/0001193125-23-275985.json","markdown":"https://secwatch.observer/filing/0001193125-23-275985.md","text":"https://secwatch.observer/filing/0001193125-23-275985.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1305253/000119312523275985/0001193125-23-275985-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1305253/000119312523275985/d316543d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T04:41:30.566231+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bd5800d3ffc0f6c58262169d4504f204abc76434","claim":"Eiger BioPharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5450(b)(1)(A), 5450(b)).","evidence_excerpt":"November 10, 2023, Eiger BioPharmaceuticals, Inc. (“Eiger”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying Eiger that it no longer satisfies the $10 million stockholders’ equity requirement for continued listing on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(b)(1)(A), or the alternatives to that requirement - a $50 million market value of listed securities or $50 million in net income in the most recent fiscal year or two of the last three fiscal years - as required by Nasdaq Listing Ru","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1305253/000119312523275985/0001193125-23-275985-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5450(b)(1)(A), 5450(b)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}